Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
7(78%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
3
33%
Ph phase_3
1
11%
Ph phase_2
5
56%

Phase Distribution

3

Early Stage

5

Mid Stage

1

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
3(33.3%)
Phase 2Efficacy & side effects
5(55.6%)
Phase 3Large-scale testing
1(11.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

7

trials recruiting

Total Trials

9

all time

Status Distribution
Active(7)
Completed(2)

Detailed Status

Recruiting4
Active, not recruiting3
Completed2

Development Timeline

Analytics

Development Status

Total Trials
9
Active
7
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (33.3%)
Phase 25 (55.6%)
Phase 31 (11.1%)

Trials by Status

active_not_recruiting333%
completed222%
recruiting444%

Recent Activity

7 active trials
Showing 5 of 9
completedphase_1

Metabolism, Excretion, and Mass Balance Study of Quemliclustat in Healthy Adult Participants (ARC-24)

NCT07364214
active_not_recruitingphase_2

A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies

NCT05329766
active_not_recruitingphase_3

Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

NCT06608927
recruitingphase_2

Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma

NCT06048484
recruitingphase_2

Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)

NCT06048133
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT07364214Phase 1

Metabolism, Excretion, and Mass Balance Study of Quemliclustat in Healthy Adult Participants (ARC-24)

Completed
NCT05329766Phase 2

A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies

Active Not Recruiting
NCT06608927Phase 3

Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Active Not Recruiting
NCT06048484Phase 2

Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma

Recruiting
NCT06048133Phase 2

Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)

Recruiting
NCT05688215Phase 1

Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

Recruiting
NCT05676931Phase 2

Study With Various Immunotherapy Treatments in Participants With Lung Cancer

Active Not Recruiting
NCT04381832Phase 1

Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

Completed
NCT05915442Phase 2

Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer

Recruiting

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9